PMCB News and Press, PharmaCyte Biotech Inc. From 08/16/21

China Finance Online (NASDAQ:JRJC) -43% after receiving Nasdaq delisting notice and announces private placement of ordinary shares and warrants Sesen Bio (NASDAQ:SESN) -36% after FDA declines to approve Sesen Bio's Vicineum bladder cancer treatment Standard Lithium (N...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The S&P (SP500) and Dow (DJI) finished up for the second week in a row. The Nasdaq (COMP.IND) ended the week down as rates steadily gained from Monday ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Among the small cap companies making big moves today is PharmaCyte Biotech (OTCMKTS: PMCB ). Indeed, PMCB stock is up nearly 60% at the time of writing on very heavy volume. Source: Shutterstock Today’s p...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced the closing of its previously anno...

PharmaCyte Biotech (OTCQB:PMCB) common stock expected to begin trading on Nasdaq on August 10, 2021, under the symbol “PMCB.” Company also announced the pricing of its previously announced underwritten public offering of ~3.53M shares. Each share of common stock is bei...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that the Company’s common s...

PharmaCyte Biotech, Inc. (OTCQB: PMCBD) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that The Nasdaq Stock Market LLC (...

PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that the production and shipping of test materials and stu...

PharmaCyte Biotech (PMCB) will effect a 1-for-1,500 reverse stock split of its common shares, leaving the company with only about 1.6M issued and outstanding shares from ~2.4B shares.Trading on reverse split-adjusted basis will commence at the opening of the market on July 12, 2021. “W...

PharmaCyte Biotech, Inc. (OTCQB: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it will effect a 1-for-1,500 r...